Dominique Recher

Dominique Recher

Auto-generated profile, based on publicly available information

Dominique Recher

Experimental Psychopathology and Psychotherapy, Department of Psychology, University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2024 in Nature Human Behaviour
Verified
Journal Article
Open access
PDF file
CSCarmen Schaeuffele
Carmen Schaeuffele
LMLaura E. Meine
Laura E. Meine
ASAva Schulz
Ava Schulz
MWMaxi C. Weber
Maxi C. Weber
AMAngela Moser
Angela Moser
BKBirgit Kleim
Birgit Kleim
Transdiagnostic cognitive behavioural psychotherapy (TD-CBT) may facilitate the treatment of emotional disorders. Here we investigate short- and long-term efficacy of TD-CBT for emotional disorders in individual, group and internet-based settings in randomized controlled trials (PROSPERO CRD42019141512). Two independent reviewers screened results from PubMed, MEDLINE, PsycINFO, Google Scholar, medRxiv and OSF Preprints published between January 2000 and June 2023, selected studies for inclusion, extracted data and evaluated risk of bias (Cochrane risk-of-bias tool 2.0). Absolute efficacy from pre- to posttreatment and relative efficacy between TD-CBT and control treatments were investigated with random-effects models. Of 56 identified studies, 53 (6,705 participants) were included in the meta-analysis. TD-CBT had larger effects on depression (g = 0.74, 95% CI = 0.57–0.92, P < 0.001) and anxiety (g = 0.77, 95% CI = 0.56–0.97, P < 0.001) than did controls. Across treatment formats, TD-CBT was superior to waitlist and treatment-as-usual. TD-CBT showed comparable effects to disorder-specific CBT and was superior to other active treatments for depression but not for anxiety. Different treatment formats showed comparable effects. TD-CBT was superior to controls at 3, 6 and 12 months but not at 24 months follow-up. Studies were heterogeneous in design and methodological quality. This review and meta-analysis strengthens the evidence for TD-CBT as an efficacious treatment for emotional disorders in different settings.

18 December 2024 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
DRDominique Recher
Dominique Recher
JRJudith Rohde
Judith Rohde
GPGiulia Da Poian
Giulia Da Poian
MHMirka Henninger
Mirka Henninger
LBLuzius Brogli
Luzius Brogli
BKBirgit Kleim
Birgit Kleim
Targeted Memory Reactivation (TMR) during sleep benefits memory integration and consolidation. In this pre-registered study, we investigated the effects of TMR applied during non-rapid eye movement (NREM) sleep following modulation and updating of aversive autobiographical memories using imagery rescripting (ImR). During 2–5 nights postImR, 80 healthy participants were repeatedly presented with either idiosyncratic words from an ImR updated memory during sleep (experimental group) or with no or neutral words (control groups) using a wearable EEG device (Mobile Health Systems Lab-Sleepband, MHSL-SB) [1] implementing a close-loop cueing procedure. Multivariate analysis were conducted to assess change score trajectories in five key emotional memory characteristics (positive and negative valence, emotional distress, arousal, and vividness) across assessments (timepoints, t) and between the study groups (TMR condition). While ImR showed significant effects on all memory characteristics (d = 0.76–1.66), there were significant additional improvements in the experimental group. Memories were significantly less vivid and afflicted with less emotional distress and arousal following ImR-words cueing. TMR during sleep in individuals’ homes was feasible and further improved some ImR’s adaptive memory effects. If replicated in clinical samples, TMR may be utilized to augment the effects of ImR and other clinical memory modulation procedures and create personalized treatment options. Such advances in emotional memory treatments are direly needed, as aversive memories are a salient feature across mental disorders, such as post-traumatic stress disorder (PTSD).

14 May 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
MMMiriam Müller-Bardorff
Miriam Müller-Bardorff
ASAva Schulz
Ava Schulz
CPChristina Paersch
Christina Paersch
DRDominique Recher
Dominique Recher
BSBarbara Schlup
Barbara Schlup
BKBirgit Kleim
Birgit Kleim
Background: Psychotherapies, such as cognitive behavioral therapy (CBT), currently have the strongest evidence of durable symptom changes for most psychological disorders, such as anxiety disorders. Nevertheless, only about half of individuals treated with CBT benefit from it. Predictive algorithms, including digital assessments and passive sensing features, could better identify patients who would benefit from CBT, and thus, improve treatment choices. Objective: This study aims to establish predictive features that forecast responses to transdiagnostic CBT in anxiety disorders and to investigate key mechanisms underlying treatment responses. Methods: This study is a 2-armed randomized controlled clinical trial. We include patients with anxiety disorders who are randomized to either a transdiagnostic CBT group or a waitlist (referred to as WAIT). We index key features to predict responses prior to starting treatment using subjective self-report questionnaires, experimental tasks, biological samples, ecological momentary assessments, activity tracking, and smartphone-based passive sensing to derive a multimodal feature set for predictive modeling. Additional assessments take place weekly at mid- and posttreatment and at 6- and 12-month follow-ups to index anxiety and depression symptom severity. We aim to include 150 patients, randomized to CBT versus WAIT at a 3:1 ratio. The data set will be subject to full feature and important features selected by minimal redundancy and maximal relevance feature selection and then fed into machine leaning models, including eXtreme gradient boosting, pattern recognition network, and k-nearest neighbors to forecast treatment response. The performance of the developed models will be evaluated. In addition to predictive modeling, we will test specific mechanistic hypotheses (eg, association between self-efficacy, daily symptoms obtained using ecological momentary assessments, and treatment response) to elucidate mechanisms underlying treatment response. Results: The trial is now completed. It was approved by the Cantonal Ethics Committee, Zurich. The results will be disseminated through publications in scientific peer-reviewed journals and conference presentations. Conclusions: The aim of this trial is to improve current CBT treatment by precise forecasting of treatment response and by understanding and potentially augmenting underpinning mechanisms and personalizing treatment. Trial Registration: ClinicalTrials.gov NCT03945617; https://clinicaltrials.gov/ct2/show/results/NCT03945617 International Registered Report Identifier (IRRID): DERR1-10.2196/42547

9 March 2022 in PsyArXiv
Verified
Preprint
Open access
MMMiriam Müller-Bardorff
Miriam Müller-Bardorff
ASAva Schulz
Ava Schulz
CPChristina Paersch
Christina Paersch
DRDominique Recher
Dominique Recher
BSBarbara Schlup
Barbara Schlup
BKBirgit Kleim
Birgit Kleim
Background: This paper describes the study protocol for our clinical trial “Optimizing Outcomes in Psychotherapy for Anxiety Disorders (OPTIMAX)” funded by the Swiss National Science Foundation (10001C_169827). The study aims to establish predictive features for forecasting response to cognitive behavior therapy (CBT) and to investigate mechanisms underlying treatment response. Methods: OPTIMAX comprises a monocentric, randomized-controlled clinical trial. We employ the Unified Treatment Protocol (UP, Barlow, 2017), an established transdiagnostic CBT protocol for treating emotional disorders, to treat patients with anxiety disorders. We use psychological questionnaires, experimental tasks, biological samples, ecological momentary assessments, activity tracking, and smartphone-based passive sensing data in order to derive a multimodal feature set for predictive modeling. We obtain assessments at different time points including baseline, mid-, and post-treatment as well as 6 and 12 months after treatment completion. Anxiety and depression symptom severity are indexed weekly during treatment. We aim to include 150 patients, randomized to CBT versus WAIT group in a 3:1 ratio. Machine learning (e.g., support vector machines, random forest) and linear regression modeling will be employed to establish predictive accuracy in forecasting treatment response. In addition to predictive modelling, we test mechanistic hypotheses, e.g., on the association between self-efficacy, dynamic symptom changes and treatment response, to elucidate mechanisms underlying treatment response. Discussion: The aim of the current trial is to improve current CBT treatment, such as the transdiagnostic unified treatment protocol employed here, by precise forecasting of treatment response and by understanding and, in the future, augmenting underpinning mechanisms and personalizing treatment. Registration: This study has been registered on clinicaltrials.gov (NCT03945617, 10 of May 2019, https://clinicaltrials.gov/ct2/show/NCT03945617)

20 November 2024 in PsyArXiv
Verified
Preprint
Open access
LMLaura Elisabeth Meine
Laura Elisabeth Meine
CSCarmen Schaeuffele
Carmen Schaeuffele
DRDominique Recher
Dominique Recher
MMMiriam Müller-Bardorff
Miriam Müller-Bardorff
CPChristina Paersch
Christina Paersch
BKBirgit Kleim
Birgit Kleim
Background: While growing research confirms the efficacy of transdiagnostic cognitive behavioral psychotherapy (TD-CBT) by examining group-level changes from pre to post-treatment, less is known about inter-individual differences and dynamic changes during therapy. Understanding different symptom trajectories and their associations with treatment outcome would allow early detection of non-responders and treatment adjustments.Methods: Patients with anxiety disorders reported on demographics, clinical history, treatment motivation, and expectations before randomization to TD-CBT or wait-list. We analyzed data from the treatment group who provided symptom ratings every session and post-treatment follow-up (N = 64, 71.9% female, age: M = 32.67, SD = 11.91). Using latent class growth analysis (LCGA), we identified symptom trajectory classes and tested whether these could be predicted from baseline data. We also examined associations between classes and treatment outcome, using multilevel modeling and considering reliable change indices. Results: LCGA revealed four distinct trajectory classes: low severity - improved (32.81%), high severity - improved (29.69%), high severity-stagnant (18.75%), and low severity - worsened (18.75%). Only number of comorbidities emerged as a significant predictor of class, with patients in the high severity - stagnant group having more comorbidities. They also showed higher symptom severity at baseline and follow-ups compared to other classes, despite clear improvement.Conclusions: During TD-CBT, latent classes of symptom change can be distinguished and point to malleable factors already present at pre-treatment. Particularly patients with high initial burden and a higher number of comorbidities may require monitoring and adaptive treatment strategies, which should be explored in future studies.

13 March 2023 in PsyArXiv
Verified
Preprint
Open access
CSCarmen Schaeuffele
Carmen Schaeuffele
LMLaura Elisabeth Meine
Laura Elisabeth Meine
ASAva Schulz
Ava Schulz
MWMaxi Weber
Maxi Weber
AMAngela Moser
Angela Moser
BKBirgit Kleim
Birgit Kleim
Transdiagnostic cognitive-behavioral psychotherapy (TD-CBT) may facilitate treatment of emotional disorders. We investigate short- and long-term efficacy of TD-CBT for emotional disorders in individual, group, and Internet-based settings in randomized controlled trials (PROSPERO CRD42019141512). Two independent reviewers screened results from PubMed, MEDLINE, PsycINFO, Google Scholar, medRxiv, and OSF Preprints published between January 2000 and January 2023, selected studies for inclusion, extracted data and evaluated risk of bias (Cochrane risk-of-bias tool 2.0). Absolute efficacy from pre- to post-treatment and relative efficacy between TD-CBT and control treatments were investigated with random-effects models. Of 56 identified studies, 53 (6610 participants) were included in the meta-analysis. TD-CBT had large effects on depression (d = 1.15, 95%CI = 1.03 - 1.28) and anxiety (d = 1.08, 95%CI = 0.95 - 1.21), from pre- to post treatment. Across treatment formats, TD-CBT was superior to waitlist (depression: g = 1.31, 95%CI = 0.88 - 1.74; anxiety: g = 1.22, 95%CI = 0.82 - 1.63) and treatment-as-usual (depression: g = 0.87, 95%CI = 0.63 - 1.11; anxiety: g = 0.94, 95%CI = 0.57 - 1.30). TD-CBT showed comparable effects to disorder-specific treatments, with indications of TD-CBT’s superiority (depression: g = 0.16, 95%CI = 0.01 - 0.32; anxiety: g = 0.15, 95%CI = 0.04 - 0.26). Large effects were reported for Internet-based TD-CBT for up to 2 years. Studies were heterogeneous in design and methodological quality. This review and meta-analysis strengthens the evidence for TD-CBT as an efficacious treatment for emotional disorders in different settings.